Karuna Therapeutics マネジメント

マネジメント基準チェック /14

Karuna Therapeuticsの CEO はBill Meuryで、 Jan2023年に任命され、の在任期間は 1.17年です。は、会社の株式の0.027%を直接所有しており、その価値は$ 3.41M 。経営陣と取締役会の平均在任期間はそれぞれ1.1年と4.3年です。

主要情報

Bill Meury

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.2yrs
CEOの所有権	0.03%
経営陣の平均在職期間	1.1yrs
取締役会の平均在任期間	4.3yrs

経営陣の近況

Recent updates

Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

Feb 20

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Nov 06

Best Performing Stocks

Sep 23

Karuna Therapeutics: This Ship Has Sailed

Sep 09

Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M

Aug 08

Karuna Therapeutics: Front-Running KarXT Phase 3

Jun 26

Karuna Therapeutics (NASDAQ:KRTX) Is In A Good Position To Deliver On Growth Plans

May 10

CEO（最高経営責任者

Bill Meury (55 yo)

1.2yrs

在職期間

Mr. William Meury, also known as Bill, served as a Partner at Hildred Capital Management LLC. He serves as Director at Crown Laboratories Inc and serves as its Chairman of the Board of Directors. He curren...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Andrew Miller	Founder and President of Research & Development	no data	US$5.77m	0.037% $ 4.6m
Stephen Brannan	Chief Medical Officer	7yrs	US$4.41m	0.095% $ 11.9m
William Meury	President	1.2yrs	データなし	0.027% $ 3.4m
Jason Brown	Chief Financial Officer	less than a year	データなし	0.037% $ 4.6m
Alexis Smith	Vice President of Corporate Affairs & Investor Relations	no data	データなし	データなし
Mia Kelley	General Counsel	4.2yrs	データなし	データなし
Frank Truslow	Senior Vice President of Corporate Development	less than a year	データなし	データなし
Jonathan Rosin	Chief Human Resources Officer	less than a year	データなし	データなし
Alan Breier	Chair of Scientific Advisory Board & Chief Clinical Advisor	no data	データなし	データなし
Ronald Marcus	Senior Vice President of Medical	3.2yrs	データなし	データなし
William Kane	Chief Commercial Officer	1.1yrs	データなし	0.013% $ 1.6m

1.1yrs

平均在職期間

57.5yo

平均年齢

経験豊富な経営陣: KRTXの経営陣は経験豊富とはみなされません ( 1.1年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
William Meury	President	1.2yrs	データなし	0.027% $ 3.4m
Alan Breier	Chair of Scientific Advisory Board & Chief Clinical Advisor	no data	データなし	データなし
James Healy	Independent Director	4.8yrs	US$336.10k	0.085% $ 10.7m
Jeffrey Jonas	Director	5.4yrs	US$326.60k	0% $ 0
Edmund Harrigan	Member of Scientific Advisory Board	3.3yrs	US$701.26k	データなし
Christopher Coughlin	Chairman	3.9yrs	US$373.15k	0% $ 0
Steven Paul	Director & Member of Scientific Advisory Board	6yrs	US$11.22m	0.37% $ 47.0m
Allan Levey	Member of Scientific Advisory Board	no data	データなし	データなし
Atul Pande	Independent Director & Member of Scientific Advisory Board	4.8yrs	US$344.60k	0% $ 0
William Potter	Member of Scientific Advisory Board	no data	データなし	データなし
Laurie Olson	Independent Director	3.6yrs	US$345.10k	0% $ 0
Richard Keefe	Member of Scientific Advisory Board	no data	データなし	データなし

4.3yrs

平均在職期間

69yo

平均年齢

経験豊富なボード: KRTXの取締役会は経験豊富であると考えられます ( 4.3年の平均在任期間)。

Karuna Therapeutics マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Chief Medical Officer notifies of intention to sell stock

Board Member exercised options to buy US$9.9m worth of stock.

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics, Inc. Announces Resignation of Steve Paul as Chief Scientific Officer and President of Research and Development

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Recent updates

Karuna Therapeutics, Inc. Files Form 15

Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Board Member exercised options to buy US$9.9m worth of stock.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Karuna Therapeutics: Getting Sold Short

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.2% to US$327

Karuna Therapeutics, Inc. Announces Resignation of Steve Paul as Chief Scientific Officer and President of Research and Development

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 23%

Consensus revenue estimates decrease by 22%

Price target increased by 9.9% to US$291

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Karuna Therapeutics, Inc. Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

New minor risk - Profitability

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for Karxt for the Treatment of Schizophrenia

Karuna Therapeutics, Inc. Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates decrease by 55%

New minor risk - Profitability

Third quarter 2023 earnings released: US$3.16 loss per share (vs US$2.38 loss in 3Q 2022)

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress

Karuna Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics, Inc. Submits New Drug Application to U.S. Food and Drug Administration for Karxt for the Treatment of Schizophrenia

We're Hopeful That Karuna Therapeutics (NASDAQ:KRTX) Will Use Its Cash Wisely

Director exercised options and sold US$2.5m worth of stock

New minor risk - Profitability

Karuna Therapeutics, Inc. Announces Chief Financial Officer Changes

Director exercised options and sold US$2.6m worth of stock

Karuna Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Director notifies of intention to sell stock

We're Not Very Worried About Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Rate

CFO & Secretary notifies of intention to sell stock

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting

Consensus revenue estimates increase by 20%

Co-Founder & COO notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$838k worth of stock

Independent Director exercised options and sold US$96k worth of stock

Chief Medical Officer exercised options and sold US$920k worth of stock

Consensus revenue estimates fall by 85%

CFO & Secretary notifies of intention to sell stock

Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

Independent Director exercised options and sold US$113k worth of stock

CFO & Secretary exercised options to buy US$2.3m worth of stock.

Chief Medical Officer exercised options and sold US$965k worth of stock

Karuna Therapeutics, Inc. Announces Executive Changes, Effective January 3, 2023

Co-Founder & COO exercised options and sold US$168k worth of stock

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates fall by 25%

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Co-Founder & COO exercised options and sold US$444k worth of stock

Chief Medical Officer exercised options and sold US$992k worth of stock

CFO & Secretary notifies of intention to sell stock

CFO & Secretary recently sold US$3.4m worth of stock

Best Performing Stocks

Chief Medical Officer exercised options and sold US$1.2m worth of stock

Karuna Therapeutics: This Ship Has Sailed

Consensus forecasts updated

Price target increased to US$236

Karuna Therapeutics, Inc. Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M

マネジメント基準チェック /14